Indaptus Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Indaptus Therapeutics (NASDAQ:INDP) reported Q4 earnings, beating estimates with an EPS of $-0.46 against an expected $-0.54. However, revenue remained unchanged from the previous year. Despite beating last quarter's EPS estimates, the share price dropped by 10% the following day.
March 13, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Indaptus Therapeutics reported a Q4 EPS of $-0.46, surpassing estimates by 15%. Revenue remained the same as last year, and past performance showed a 10% share price drop following an earnings beat.
Despite beating EPS estimates, the unchanged revenue and historical context of a share price drop following an earnings beat suggest a potential short-term negative impact on INDP's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100